Abstract
Elevated levels of oxidative DNA lesions have been noted in many tumors and such damage is strongly implicated in the etiology of cancer. The cumulative risk of cancer increases with the fourth power of age and is associated with an accumulation of oxidative DNA damage. Many agents, synthetic or natural, that can inhibit mutation have been depicted as cancer chemopreventive agents. Antimutagenicity of the 3-hydroxy-3-methylgutaryl-CoA (HMG-CoA) reductase inhibitors atorvastatin and lovastatin was studied using the Ames Salmonella typhimurium assay. Directly acting mutagens, sodium azide (NaN3) and 4-nitro-o-phenylenediamine (NPDA), were used to induce mutation in Salmonella strains TA98 and TA100. The antimutagenicity of lovastatin and atorvastatin was found to be significant (p < 0.01) and dose-dependent. The percentage inhibition of a 3 mg lovastatin-treated plate was found to be 79.9% and 61.8% against NPDA- and NaN3-induced mutation to TA98 and TA100, respectively. Atorvastatin (0.5 mg/plate) inhibited NPDA-and NaN3-induced mutation to TA98 and TA100 by 78.6% and 45.5%, respectively. Atorvastatin showed antimutagenic activity at lower concentrations than lovatstatin. The results of the present study regarding the antimutagenic activity of atorvastatin and lovastatin suggested their therapeutic application as cancer chemopreventive agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- APC:
-
adenomatus polyposis coli
- ATC:
-
anaplastic thyroid carcinomas
- DMSO:
-
dimethyl sulfoxide
- HMG-CoA:
-
3-hydroxy-3-methylgutaryl-CoA
- MDA:
-
malondialdehyde
- NPDA:
-
4-nitro-o-phenylenediamine
- NaN3 :
-
sodium azide
- SR:
-
spontaneous revertants
References
Appleton BS, Landers RE. Oil gavage effects in tumor incidence in the national toxicology programmers two year carcinogenesis bio assay. Adv Exp Med Biol. 1985;206:99–103.
Armstrong B, Doll R. Environmental factor and cancer incidence and mortality in different countries, with special reference to dietary practice. Int J Cancer. 1975;15:617–21.
Balmin A, Brown K. Oncogene activation in chemical carcinogenesis. Adv Cancer Res. 1988;51:147–82.
Beltowski J. Statins and modulation of oxidative stress. toxicol Mech Methods. 2005;15:61–92.
Bos JL. Ras oncogene in human cancer: a review. Cancer Res. 1989;49:4682–9.
Cerutti P, Ghosh R, Oya Y, Amstad P. The role of the cellular antioxidant defense in oxidant carcinogenesis. Environ Health Perspect. 1994;102:123–30.
Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–9.
Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem. 1998;70:2397–404.
Giacosa A, Filiberti R, Hill MJ, Faivre J. Vitamins and cancer chemoprevention. Eur J Cancer Prev. 1997;6:S47–54.
Ip C. Review of the effects of trans fatty acids, oleic acid, n−3 polyunsaturated fatty acids and conjugated linolenic acid on mammary carcinogenesis in animals. Am J Clin Nutr. 1997;66:1523–29s.
Jakobisiak M, Golab J. Potential antitumor effects of statins (review). Int J Oncol. 2003;23:1055–69.
Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 1994;54:2015–24s.
Koch WH, Henrikson EN, Kupchella E, Cebula TA. Salmonella typhimurium strain TA100 differentiates several classes of carcinogens and mutagens by base substitution specificity. Carcinogenesis. 1994;15:79–88.
Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A Phase I–II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21:579–83.
Maron DM, Ames BN Revised methods for the salmonella mutagenicity test. Mutat Res. 1983;113:173–215.
Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 1992;50:859–62.
Moller P, Wallin H. Adduct formation, mutagenesis and nucleotide excision repair of DNA damage produced by reactive oxygen species and lipid peroxidation product. Mutat Res. 1998;410:271–8.
Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261–8.
Ray G, Batra S, Shukla NK, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat. 2000;59:163–70.
Rugge M, Shio YH, Correa P, Baffa R, Di Mario F. Immunohistochemical evidence of P53 over expression in gastric epithelial dysplasia. Cancer Epidemiol Biomarkers Prev. 1992;1:551–4.
Struewing JP, Hartge P, Wacholder S, Backer SM, Berlin M, McAdams M, Timmerman MM. The risk of cancer associated with specific mutations of BRCA1 and BRCA 2 among Ashkenazi Jews. N Engel J Med. 1997;336:1401–8.
Sun SY, Hail N, Lotan JR. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 2004;96:662–72.
Tahara E. Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol. 1990;116:121–31.
Vaca CE, Wilhelm J, Harms-Rihsdahl M. Interaction of lipid peroxidation product with DNA. A Review. Mutat Res Rev Genet Toxicol. 1988;195:137–46.
Wright PA, Williams GT. Molecular biology and gastric carcinoma. Gut. 1993;34:145–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ajith, T.A., Soja, M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biol Toxicol 22, 269–274 (2006). https://doi.org/10.1007/s10565-006-0064-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-006-0064-6